Does Rallies show 13F holders for OGN?

Yes. Rallies tracks hedge fund and 13F ownership data for OGN, including fund names, share counts, latest tracked quarter, and position changes when available.

Is OGN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for OGN. It does not provide personalized investment advice.

OGN (Organon & Co.) Stock Analysis - Hedge Fund Holdings

Organon & Co. (OGN) is a publicly traded Healthcare sector company. As of May 21, 2026, OGN trades at $13.40 with a market cap of $3.52B and a P/E ratio of 14.29. OGN moved +0.34% today. Year to date, OGN is +80.91%; over the trailing twelve months it is +53.65%. Its 52-week range spans $5.69 to $19.41. Analyst consensus is neutral with an average price target of $11.25. Rallies surfaces OGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns OGN stock?

Hedge funds tracked by Rallies that own OGN include Bridgewater Associates, Mangrove Partners, and Pinebridge Investments. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Organon & Co..

OGN Key Metrics

Key financial metrics for OGN
Metric	Value
Price	$13.40
Market Cap	$3.52B
P/E Ratio	14.29
EPS	$0.94
Dividend Yield	0.02%
52-Week High	$19.41
52-Week Low	$5.69
Volume	2
Avg Volume	0
Revenue (TTM)	$6.16B
Net Income	$246.00M
Gross Margin	52.81%

Top Hedge Funds Holding OGN

Bridgewater Associates holds 594.48K shares of OGN, changed -34.62% as of Mar 31, 2026.
Mangrove Partners holds 73.16K shares of OGN, changed -21.60% as of Mar 31, 2026.
Pinebridge Investments holds 41.50K shares of OGN, changed -5.21% as of Jun 30, 2025.

Latest OGN News

Legal Challenge Targets Organon $14-Per-Share Sale to Sun Pharma — May 14, 2026
Organon Q1 Revenue $1.46B, Earnings $0.71 Miss Estimates — Apr 30, 2026
Sun Pharmaceutical to Acquire Organon for $11.75 Billion at $14 Per Share — Apr 27, 2026
Organon Soars 25% on Sun Pharma’s $12 Billion All-Cash Offer — Apr 10, 2026
Organon CEO Resignation Follows Probe as 2025 Revenue Falls 3% to $6.2B — Mar 24, 2026

Recent OGN Insider Trades

Holzbaur Lynette sold 26.45K (~$353.08K) on May 6, 2026.
Holzbaur Lynette bought 26.45K (~$353.08K) on May 6, 2026.
COX CARRIE SMITH bought 65.40K (~$501.76K) on Nov 12, 2025.

OGN Analyst Consensus

5 analysts cover OGN: 0 strong buy, 0 buy, 4 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $11.25.

Common questions about OGN

Who owns OGN stock?: Hedge funds tracked by Rallies that own OGN include Bridgewater Associates, Mangrove Partners, and Pinebridge Investments. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Organon & Co..
Does Rallies show 13F holders for OGN?: Yes. Rallies tracks hedge fund and 13F ownership data for OGN, including fund names, share counts, latest tracked quarter, and position changes when available.
Is OGN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for OGN. It does not provide personalized investment advice.